

WHAT IS CLAIMED IS:

1. A method of modulating the trafficking of systemic memory T cells in a mammalian host, the method comprising:

administering an effective amount of a CCR4 modulating agent, in a dose
5 effective to modulate said trafficking of systemic memory T cells.

2. The method of Claim 1, wherein said administration provides for a prolonged localized concentration of said CCR4 modulating agent.

10 3. The method of Claim 2, wherein said systemic memory T cells are CD4⁺.

4. The method according to Claim 2, wherein said memory T cells are CD8⁺.

5. The method according to Claim 3, wherein said systemic memory T cells
15 are CD45Ra⁻, and integrin $\alpha 4\beta 7$.

6. The method of Claim 5, wherein said systemic memory T are further characterized as CLA⁺.

20 7. The method of Claim 6, wherein said localized concentration of said CCR4 modulating agent is cutaneous.

8. The method of Claim 1, wherein said CCR4 modulating agent is a CCR4 agonist.

25

9. The method of Claim 8, wherein said CCR4 agonist is selected from the group consisting of TARC and MDC.

10. The method of Claim 1, wherein said CCR4 modulating agent is a CCR4 antagonist.

11. The method of Claim 10, wherein said CCR4 antagonist is an antibody.

12. The method of Claim 11, wherein said antibody is a monoclonal antibody.

13. A method of modulating the trafficking of CCR4+ skin homing leukocytes to cutaneous tissue or skin, the method comprising:

administering an effective amount of a CCR4 modulating agent, wherein said agent modulates the interaction between CCR4 and a ligand.

14. The method according to Claim 13, wherein said leukocyte is a lymphocyte.

15. The method according to Claim 14, wherein said lymphocyte is a T cell.

16. The method according to Claim 15, wherein said T cell is further characterized as CD4⁺.

17. The method according to Claim 16, wherein said T cell is further characterized as CD45Ra⁻, and integrin $\alpha 4\beta 7$ ⁻.

18. A method of treating inflammatory skin disease, the method comprising:
administering to a patient an effective amount of a CCR4 antagonist, wherein said CCR4 antagonist interferes with the interaction between CCR4 and a ligand.

19. The method according to Claim 18, wherein said CCR4 ligand is TARC or MDC.

20. The method according to Claim 18, wherein said CCR4 antagonist is an
5 antibody.

21. The method according to Claim 20, wherein said antibody binds to CCR4.

22. The method according to Claim 20, wherein said antibody binds to a CCR4
10 ligand.